
    
      Participants are first being informed about potential benefits and risks of the study and are
      required to give written consent. After that participants will undergo detailed phone screen
      to determine eligibility for study entry. At week 0, participants who meet eligibility
      requirements will be prescribed atorvastatin (40 mg, once in the evening) in an open-label
      manner.
    
  